In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Featured article: "Lessons learned: establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays – navigating the transition from research to clinical practice"
Using thyroglobulin as a biomarker and an immuno-multiple reaction monitoring mass spectrometry (MS)-based assay as a model, we present the lessons learned of the translation process of developing a protein MS assay in a Clinical Laboratory Improvement Amendments compliant laboratory. Our experience shed light on the practical aspects of international collaboration in developing such assays and offer a comprehensive guide to accelerate the adoption of MS-based protein assays in clinical laboratories, thereby enhancing patient care.
Articles
-
-
The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies
-
Plasma proteomic characterization of colorectal cancer patients with FOLFOX chemotherapy by integrated proteomics technology
-
Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
-
Quantitative proteomic analysis of HER2 protein expression in PDAC tumors
-
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
-
Basics and recent advances of two dimensional- polyacrylamide gel electrophoresis
-
Nanotechnologies in Glycoproteomics
-
Recent advances in mass spectrometry based clinical proteomics: applications to cancer research
-
Using phosphoproteomics data to understand cellular signaling: a comprehensive guide to bioinformatics resources
The Correction to this article has been published in Clinical Proteomics 2024 21:20
Archival content
Trezvuy - Fotolia
Have an idea for a new thematic series?
Make a suggestion here
Aims and scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Editor's profile
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Featured collections
Liquid biopsy applications of proteomics
Guest edited by Samir Hanash, Stephen Pennington, Jochen Schwenk
Read more
Bioinformatic approaches for clinical proteomics: too many choices and no standardization
Guest edited by Ventzislava Hristova, Thang Pham, Bing Zhang
Read more
Spatial proteomics
Guest edited by Hui Zhang and Yuanwei Xu
Read more
Clinical translation of targeted proteomics
Guest edited by Tiannan Guo, Ed Nice, Stephen Pennington, Henry Rodriguez
Read more
Annual Journal Metrics
-
2022 Citation Impact
3.8 - 2-year Impact Factor
3.8 - 5-year Impact Factor
0.873 - SNIP (Source Normalized Impact per Paper)
0.941 - SJR (SCImago Journal Rank)2023 Speed
11 days submission to first editorial decision for all manuscripts (Median)
159 days submission to accept (Median)2023 Usage
434,196 downloads
385 Altmetric mentions